Literature DB >> 10596374

Generation of recombinant antibodies.

S M Kipriyanov1, M Little.   

Abstract

Recombinant antibody technology is opening new perspectives for the development of novel therapeutic and diagnostic agents. In this review we focus on advances in the generation of both genetically engineered humanized and fully human monoclonal antibodies. Methods for their production in different expression systems are also discussed.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10596374     DOI： 10.1385/MB:12:2:173

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN： 1073-6085            Impact factor:   2.695


  233 in total

1.  Selection of phage-displayed antibodies specific for a cytoskeletal antigen by competitive elution with a monoclonal antibody.

Authors:  E V Meulemans; R Slobbe; P Wasterval; F C Ramaekers; G J van Eys
Journal:  J Mol Biol       Date:  1994-12-09       Impact factor: 5.469

2.  High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site.

Authors:  C F Barbas; L R Languino; J W Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

3.  High level production of soluble single chain antibodies in small-scale Escherichia coli cultures.

Authors:  S M Kipriyanov; G Moldenhauer; M Little
Journal:  J Immunol Methods       Date:  1997-01-15       Impact factor: 2.303

4.  Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog.

Authors:  K O Webber; Y Reiter; U Brinkmann; R Kreitman; I Pastan
Journal:  Mol Immunol       Date:  1995-03       Impact factor: 4.407

5.  A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL.

Authors:  C R Jost; J A Titus; I Kurucz; D M Segal
Journal:  Mol Immunol       Date:  1996-02       Impact factor: 4.407

6.  Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies.

Authors:  F Kolbinger; J Saldanha; N Hardman; M M Bendig
Journal:  Protein Eng       Date:  1993-11

7.  A new vector for the high level expression of chimeric antibodies in myeloma cells.

Authors:  K Shitara; K Nakamura; Y Tokutake-Tanaka; M Fukushima; N Hanai
Journal:  J Immunol Methods       Date:  1994-01-03       Impact factor: 2.303

8.  High level expression on a chimeric anti-ganglioside GD2 antibody: genomic kappa sequences improve expression in COS and CHO cells.

Authors:  L A Fouser; S L Swanberg; B Y Lin; M Benedict; K Kelleher; D A Cumming; G E Riedel
Journal:  Biotechnology (N Y)       Date:  1992-10

9.  Isolation of neutralizing anti-C5a monoclonal antibodies from a filamentous phage monovalent Fab display library.

Authors:  R S Ames; M A Tornetta; C S Jones; P Tsui
Journal:  J Immunol       Date:  1994-05-01       Impact factor: 5.422

10.  A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.

Authors:  U Brinkmann; Y Reiter; S H Jung; B Lee; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 12.779
View more
  9 in total

Review 1.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

2.  Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.

Authors:  Xiaoling Wang; Tapan K Das; Satish K Singh; Sandeep Kumar
Journal:  MAbs       Date:  2009-05-29       Impact factor: 5.857

3.  A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery.

Authors:  Marcus Duvall; Norma Bradley; Ryan N Fiorini
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

4.  Blocking monocyte transmigration in in vitro system by a human antibody scFv anti-CD99. Efficient large scale purification from periplasmic inclusion bodies in E. coli expression system.

Authors:  Diego Moricoli; William Anthony Muller; Damiano Cosimo Carbonella; Maria Cristina Balducci; Sabrina Dominici; Richard Watson; Valentina Fiori; Evan Weber; Maurizio Cianfriglia; Katia Scotlandi; Mauro Magnani
Journal:  J Immunol Methods       Date:  2014-05-04       Impact factor: 2.303

Review 5.  Translating basic mechanisms of IgG effector activity into next generation cancer therapies.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Cancer Immun       Date:  2012-05-01

6.  Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.

Authors:  Bohua Li; Hao Wang; Jianxin Dai; Junjie Ji; Weizhu Qian; Dapeng Zhang; Sheng Hou; Yajun Guo
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

7.  EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.

Authors:  Gianluca Sala; Ilario Giovanni Rapposelli; Reza Ghasemi; Enza Piccolo; Sara Traini; Emily Capone; Cosmo Rossi; Angela Pelliccia; Annalisa Di Risio; Maurizia D'Egidio; Nicola Tinari; Raffaella Muraro; Stefano Iacobelli
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

8.  Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies.

Authors:  Matthias Eder; Björn Wängler; Stefan Knackmuss; Fabrice LeGall; Melvyn Little; Uwe Haberkorn; Walter Mier; Michael Eisenhut
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-29       Impact factor: 9.236

9.  The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi.

Authors:  Vivi Joosten; Christien Lokman; Cees AMJJ Van Den Hondel; Peter J Punt
Journal:  Microb Cell Fact       Date:  2003-01-30       Impact factor: 5.328
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.